Search Page

1

Cite

Share

Pitavastatin - a novel therapeutic milestone.

Ohbayashi H. Ohbayashi H. Drugs Today (Barc). 2010 Oct;46(10):765-75. doi: 10.1358/dot.2010.46.10.1509558. Drugs Today (Barc). 2010. PMID: 21076713 Review.

Cite

Share

2

Cite

Share

Serum periostin reflects dynamic hyperinflation in patients with asthma.

Asano T, Ohbayashi H, Ariga M, Furuta O, Kudo S, Ono J, Izuhara K. Asano T, et al. Among authors: ohbayashi h. ERJ Open Res. 2020 Jul 20;6(2):00347-2019. doi: 10.1183/23120541.00347-2019. eCollection 2020 Apr. ERJ Open Res. 2020. PMID: 32714962 Free PMC article.

Cite

Share

3

Cite

Share

Matrix metalloproteinases in lung diseases.

Ohbayashi H. Ohbayashi H. Curr Protein Pept Sci. 2002 Aug;3(4):409-21. doi: 10.2174/1389203023380549. Curr Protein Pept Sci. 2002. PMID: 12370004 Review.

Cite

Share

4

Cite

Share

Matrix metalloproteinase-9 and airway remodeling in asthma.

Ohbayashi H, Shimokata K. Ohbayashi H, et al. Curr Drug Targets Inflamm Allergy. 2005 Apr;4(2):177-81. doi: 10.2174/1568010053586246. Curr Drug Targets Inflamm Allergy. 2005. PMID: 15853739 Review.

Cite

Share

5

Cite

Share

Neutrophil elastase inhibitors as treatment for COPD.

Ohbayashi H. Ohbayashi H. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. doi: 10.1517/13543784.11.7.965. Expert Opin Investig Drugs. 2002. PMID: 12084007 Review.

Cite

Share

6

Cite

Share

Open-label study to evaluate the treatment continuation rate after a dose reduction of lubiprostone due to onset of adverse events.

Ohbayashi H, Sato Y, Kiuchi M, Asano T, Nagazumi A, Kimura T. Ohbayashi H, et al. Expert Rev Gastroenterol Hepatol. 2021 Mar;15(3):333-342. doi: 10.1080/17474124.2021.1833714. Epub 2020 Nov 18. Expert Rev Gastroenterol Hepatol. 2021. PMID: 33206011

Cite

Share

7

Cite

Share

Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study.

Hozawa S, Ohbayashi H, Tsuchiya M, Hara Y, Lee LA, Nakayama T, Tamaoki J, Fowler A, Nishi T. Hozawa S, et al. Among authors: ohbayashi h. J Asthma Allergy. 2021 Jul 6;14:809-819. doi: 10.2147/JAA.S305918. eCollection 2021. J Asthma Allergy. 2021. PMID: 34262299 Free PMC article.

Cite

Share

8

Cite

Share

Comparison of User Satisfaction and Preference with Inhalant Devices Between a Pressurized Metered-Dose Inhaler and Ellipta in Stable Asthma Patients: A Randomized, Crossover Study.

Ohbayashi H, Asano T, Kudo S, Ariga M. Ohbayashi H, et al. Pulm Ther. 2021 Jun;7(1):171-187. doi: 10.1007/s41030-021-00149-6. Epub 2021 Mar 2. Pulm Ther. 2021. PMID: 33651301 Free PMC article.

Cite

Share

9

Cite

Share

[CHARACTERISTICS OF BUDEFORU^® FOR BUDESONIDE AND FORMOTEROL MIXTURE].

Kondo T, Tanigaki T, Hibino M, Tajiri S, Horiuchi S, Ohbayashi H. Kondo T, et al. Among authors: ohbayashi h. Arerugi. 2022;71(1):37-41. doi: 10.15036/arerugi.71.37. Arerugi. 2022. PMID: 35173123 Japanese.

Cite

Share

10

Cite

Share

Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.

Nakamura Y, Hozawa S, Sagara H, Ohbayashi H, Lee LA, Crawford J, Tamaoki J, Nishi T, Fowler A. Nakamura Y, et al. Among authors: ohbayashi h. Curr Med Res Opin. 2021 Sep;37(9):1657-1665. doi: 10.1080/03007995.2021.1944849. Epub 2021 Jul 14. Curr Med Res Opin. 2021. PMID: 34162298 Clinical Trial.

Cite

Share